CS Paper Radar

Clinical Evidence-Guided Residual Learning for Medication Recommendation with Dynamic DDI Regularization

Zesheng Li, Chengchang Pan, Honggang Qi

cs.LG cs.IR ·submitted 2026-11-07 09:34 UTC · v1
code/data

Abstract

Medication recommendation must combine patient-specific treatment evidence with the interaction structure of a prescription. The central challenge is to determine which evidence supports each medication and how strongly to regularize interactions while preserving predictive quality. We propose EviDrug, a clinical evidence-guided residual learning framework. Its clinical-memory backbone integrates a self-trained visit-aware encoder, training-case memory and one medication-set interaction block to establish a patient-specific prescription. A gated refinement head combines the backbone states with clinical associations and history-conditioned medication identities through bounded logit corrections. Drug-drug interaction (DDI) feedback adapts regularization strength using training-query predictions. Across MIMIC-IV, NWICU and SICdb, EviDrug leads twelve published-method baselines in AP, F1 and Jaccard, improving AP by 2.26, 2.06 and 1.71 percentage points over the strongest comparator. These gains come at lower parameter and runtime costs than MetaDrug. Matched controls demonstrate DDI reductions with stable predictive quality. Code is available at https://github.com/LIZESHENG13/EviDrug.

Comment
13 pages, 6 figures, 8 tables. Supplementary PDF and detailed result tables are included as ancillary files. Code: https://github.com/LIZESHENG13/EviDrug

Closest papers

Nearest neighbours by meaning across the whole index.

MoEDDI: Semantic Mixtures of Experts for Long Tailed Drug Drug Interaction Prediction

cs.LG ·2026-10-31 ·Dinh Tan Nguyen, Hien Quang Kha, Minh-Toan Dinh, Xuan-Huy Nguyen, Phu. D Ho +3 more
similarity 0.67
Abstract

Descriptor-based drug--drug interaction (DDI) models typically apply a single global predictor despite heterogeneous physicochemical evidence and severely long-tailed labels. We introduce \textbf{MoEDDI (Mixture-of-Experts for Drug--Drug Interaction prediction)}, a chemically organized mixture-of-experts that routes overlapping descriptor families using low-dimensional statistics and combines their sparse top-$2$ mixture with a global T-DDI pathway through a residual logit correction. The residual parameterization can exactly preserve a supplied T-DDI checkpoint at initialization, although the evaluated models are trained from scratch. Across complete test partitions with 178, 86, and 92 classes, MoEDDI improves macro-F1 over reproduced seed-2026 T-DDI baselines from 0.8284 to 0.8485, 0.4729 to 0.6536, and 0.1807 to 0.4671. On the 3,780-feature corpus, the lowest-support group (89 classes with fewer than 50 test examples) shows the largest mean classwise gain (+3.30 F1 points). Calibration improves on one corpus but worsens on two. These single-seed results support semantic conditional specialization while motivating matched ablations and distribution-shift evaluation.

0.19

HADRec: A Hierarchy-Aware Drug Recommendation Framework by Fusing Molecular Knowledge and Electronic Health Record

cs.LG ·2026-10-01 ·Junke Wang, Hongshun Ling, Li Zhang, Jinjing Wu, Tong Shao +2 more
similarity 0.66
Abstract

Accurate medication recommendation is central to clinical decision-making, directly determining therapeutic efficacy and patient safety. However, existing methods suffer from two key limitations: drugs are often abstracted as discrete tokens, ignoring their molecular structures and pharmacological mechanisms, and the commonly used "flat" recommendation paradigm fails to leverage the hierarchical logic of the internationally standardized Anatomical Therapeutic Chemical (ATC) classification system. To address these issues, we propose HADRec, a Hierarchy-Aware Drug Recommendation framework that integrates molecular knowledge with electronic health records (EHRs). HADRec employs LLaMA-7B to encode clinical notes for rich patient representations and ChemBERTa to encode drug Simplified Molecular Input Line Entry System strings, building a global molecular knowledge base. A cross-attention mechanism then performs deep multimodal fusion between patient states and drug features. The framework further incorporates a hierarchical predictor and a novel consistency constraint loss to enforce strict adherence to ATC logical dependencies. Extensive experiments on MIMIC-III demonstrate that HADRec achieves state-of-the-art performance across Jaccard, F1, and PR-AUC. External validation on MIMIC-IV confirms strong generalization under distribution shifts, and calibration analysis shows well-calibrated predictive confidence on MIMIC-IV with ECE = 0.04, and Brier = 0.06. Counterfactual evaluation reveals clinically aligned reasoning, disentangling disease-specific treatments from general care. Together, these results establish HADRec as a high-performance, interpretable, and clinically grounded pathway toward safe and reliable AI-driven medication recommendation.

0.14

ARMED: Adaptive Retrieval-Augmented Medication Recommendation

cs.LG cs.AIcs.CLcs.IR ·2026-10-12 ·Kyungkeon Chung, Se Un Park, Hyejin Lee, Junyoung Park
published similarity 0.65
Abstract · Accepted at ICTAI 2026

Medication recommendation requires jointly considering diagnoses, comorbidities, longitudinal patient history, and treatment interactions. Although recent retrieval-augmented generation approaches using language models have shown promise for clinical recommendation, most existing systems rely on fixed retrieval pipelines that cannot adapt to diverse clinical retrieval scenarios and may introduce noisy or irrelevant evidence. We propose ARMED, an adaptive clinical RAG framework that dynamically expands retrieval according to retrieval sufficiency and current-admission relevance. ARMED first observes the initial retrieval outcome and selectively performs supplementary or fallback multi-query retrieval when additional evidence is needed. The framework also incorporates a relevance gate that activates only clinically relevant same-patient history and organizes retrieved evidence into structured query-level clinical evidence. Experiments on MIMIC-IV demonstrate that ARMED consistently outperforms previous static retrieval baselines and improves overall medication recommendation quality. By combining locally runnable small language models with adaptive retrieval, ARMED supports medication recommendation without relying on external language model APIs or task-specific fine-tuning.

0.25

HEM-Med: A Hierarchical Agentic Memory Framework for Safe Multi-Center Medication Recommendation

cs.AI cs.IR ·2026-10-14 ·Min Xiao, Jin Li, Shoujin Wang, Yeguang Zhen, Yishuo Li +1 more
similarity 0.65
Abstract · BIBM 2026

Medication recommendation (MR) is critical for clinical decision support. While existing MR methods are mostly designed for single-center learning, where only one independent hospital is involved, multi-center MR with hospitals of different scales has become increasingly demanding in practice. In multi center settings, abundant data from large medical centers can improve recommendation performance for low-resource centers. Despite a few preliminary attempts on this task, two critical gaps remain. Gap 1: Existing multi-center methods fail to disentangle transferable cross-hospital clinical experience from hospital-specific prescribing patterns, limiting clinical feasibility and physician acceptance. Gap 2: They commonly overlook multi label safety constraints of MR, including drug-drug interaction risks and local formulary feasibility, which are essential for safe real-world deployment. To address these gaps, we propose HEM-Med, a novel hierarchical agentic memory framework for multi-center MR. To address Gap 1, we design a disentangled hierarchical memory module that builds patient-level medication context attribution records and disentangles them into cross hospital experience memory and hospital-specific residual memory. To address Gap 2, we introduce a safety-aware medication set generation module, which integrates dual-level experience retrieval with safety-aware set decoding to produce clinically relevant, safer, and locally adaptive medication recommendations. Experiments on a real-world multi-center eICU dataset show that HEM-Med outperforms representative transfer learning, LLM-based, and MR baselines in terms of both recommendation accuracy and safety.

0.07

From Scores to Safe Sets: Exact Safety--Constrained Decoding for Medication Recommendation

cs.AI ·2026-10-21 ·Animesh Agarwal, Meysam Ghaffari, Nina Fatehi, Anushka Swarup, Carlos Morato
similarity 0.64
Abstract

Recent generative medication recommendation systems ultimately produce sets of drugs, but drug--drug interaction (DDI) constraints depend on the set as a whole. A natural post-hoc approach is to first predict medications and then locally repair interacting pairs by removing one drug at a time. We ask whether this local repair step itself introduces avoidable error. Using fixed medication scores from FLAME's frozen classifier on MIMIC-III, we compare increasingly strong local repair strategies with an exact global decoder while holding the scores, output size, and DDI constraint fixed. The global decoder jointly selects the highest-scoring feasible medication set using mixed-integer linear programming. Across validation and test splits, global decoding consistently achieves higher Jaccard similarity than greedy repair, degree-aware repair, and degree-aware repair strengthened with exhaustive 1-swap local search. Its advantage is small under loose DDI constraints and becomes larger as the constraint tightens; on the test split it reaches +0.0064 Jaccard over the strongest local baseline at the strict DDI operating point. The finding also holds across a fine accuracy--DDI sweep at matched realized DDI exposure and under three score representations. At the strict setting, global decoding retains more true-positive medications while removing more false positives. These results show that medication recommendation is not only a representation-learning problem: even with a frozen clinical model, how its scores are converted into a constrained medication set can materially affect the final prediction.

0.23

Advancing Clinical Trial Outcome Prediction with Domain-Specific Large Language Models

cs.AI ·2026-10-30 ·Burak Bakkar, Hana Moalla, Mohamed Salem Jedidi, Haifa Ben Messaoud, Nicolas Lopez Carranza
benchmark similarity 0.64
Abstract

Clinical trial failures are a major barrier to efficient drug development, incurring substantial costs and delaying patient access to effective therapies. Structured approaches such as the Hierarchical Interaction Network (HINT) predict trial outcomes by explicitly modelling interactions between drugs, diseases and protocols, but make limited use of the free text in trial registrations. We evaluate two domain-specific language models, BioBERT (108M parameters) and BioMistral (7B parameters), for phase-level outcome prediction on the TOP benchmark (12,477 trials), representing each trial as text built from ten ClinicalTrials.gov fields. We compare fine-tuning (full fine-tuning for BioBERT, low-rank adaptation for BioMistral) with probing, in which the pretrained model is frozen and only a lightweight classifier is trained on its embeddings. On the held-out test set of each phase, all four language-model variants achieved higher ROC-AUC (0.613--0.772) and PR-AUC (0.649--0.901) than the published HINT results, corresponding to relative PR-AUC gains of 10--20\%. F1 differences were small and mixed, and no model, including HINT, clearly exceeded the F1 of a trivial classifier that predicts success for every trial. Under the configurations tested, probing performed comparably to fine-tuning: fine-tuned models scored highest on ROC-AUC and PR-AUC in Phases I and II, and frozen BioMistral embeddings in Phase III (ROC-AUC 0.772; PR-AUC 0.901), although most differences between variants were below 0.03 and were not tested for significance. These results suggest that pretrained biomedical representations already encode signal relevant to trial outcome, and that probing is a computationally cheaper alternative to fine-tuning for this task.

0.22

Pretrained Medical Representations for the Practical Screening of Drug Repositioning Candidates

cs.LG ·2026-09-17 ·Yuhei Fujioka, Daitaro Misawa, Shingo Fukuma
published similarity 0.64
Abstract · Accepted at ICML 2026 AI for Science Workshop

Representation learning from medical code sequences in electronic health records and medical claims data has been successful in various clinical applications, such as those regarding disease prediction. However, significant challenges remain in extending this approach to the discovery of scientific hypotheses. One reason is that many existing BERT-based models fail to adequately capture the hierarchical structure of medical codes and the complex interactions between diagnoses and treatments. To address these limitations, we propose a new unified pre-training framework that explicitly integrates hierarchical sub-token aggregation, partial masking, and cross-reference mechanisms. The proposed model consistently outperformed existing methods on both pre-training objectives and downstream clinical event prediction tasks, including the onset of dementia and hospitalization. We also conducted an in silico drug repositioning case study targeting Alzheimer's disease. In the hypothesis generation step, our approach successfully rediscovered known promising drugs in a data-driven manner without relying on such external knowledge sources as the literature. Subsequently, in the hypothesis prioritization step, we introduced a Task-Adaptive Representation Approach to alleviate the over-encoding of historical prescription information within diagnostic vectors, enabling the robust prioritization of generated hypotheses. This study establishes an exploratory screening workflow for hypothesis generation and prioritization based on observational associations. Importantly, this framework is not intended to provide causal evidence, but rather to identify promising candidates for subsequent rigorous causal inference. Overall, this study demonstrates that domain-informed representation learning combined with task-adaptive representation control can enable a practical hypothesis discovery workflow.

0.23

Entropy-Guided Reverse-Causal AI to Identify Upstream Bottleneck Genes for Alzheimer's Drug Discovery

cs.CE ·2026-10-06 ·Victor O. K. Li, Jacqueline C. K. Lam, Yang Han, Lawrence Y. L. Cheung
similarity 0.63
Abstract

Identifying upstream regulators that connect several disease processes to therapeutic interventions is a central objective in Alzheimer's disease drug discovery. We propose an entropy-guided reverse-causal framework that makes candidate bottleneck genes the organizing link between disease mechanisms, pathways, molecular targets and drugs. The methodology integrates five stages: an Alzheimer's-specific knowledge graph with language-model assistance and expert review; reverse tracing from drugs to candidate genes; entropy-guided prioritization; forward propagation to drugs and complementary combinations; and staged validation with evidence feedback. The novelty lies in integrating upstream bottleneck identification, entropy-guided prioritization and iterative therapeutic selection within a dynamic, bidirectional discovery architecture. We demonstrate its molecular tracing and gene-prioritization components in a computational feasibility study using DeepDrug2 and MSigDB pathway annotations. Tracing amlodipine, indapamide and atorvastatin through a network of 11,300 molecular and drug nodes identifies 46 routes to nine genes. EGFR is the leading candidate, supported by 26 routes from all three drugs; MME and MAF rank next. These results show how pharmacological starting points can identify shared candidate genes with defined molecular connections. The framework's scientific significance lies in connecting convergent disease mechanisms to systematic intervention selection, with preservation of cognition and independence as the translational objective.

0.10